# Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2013

- Company: [Mesa Laboratories Inc](/companies/mlab.md) (CIK 724004)
- Form: 10-Q
- Filed: 2014-02-05
- Accepted by EDGAR: Feb 5, 2014, 10:00 ET
- Period: 2013-12-31
- Accession: 0001104659-14-006596
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/724004/000110465914006596/a13-26561_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/724004/000110465914006596/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-10-01 to 2013-12-31 | $13.1m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2013-04-01 to 2013-12-31 | $37.0m | us-gaap:SalesRevenueNet |
| Gross profit | 3 months, 2013-10-01 to 2013-12-31 | $7.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2013-04-01 to 2013-12-31 | $22.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2013-10-01 to 2013-12-31 | $524.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2013-04-01 to 2013-12-31 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2013-10-01 to 2013-12-31 | $2.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2013-04-01 to 2013-12-31 | $8.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2013-10-01 to 2013-12-31 | $981.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2013-04-01 to 2013-12-31 | $3.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-10-01 to 2013-12-31 | $1.7m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months, 2013-04-01 to 2013-12-31 | $5.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2013-10-01 to 2013-12-31 | $0.48 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2013-04-01 to 2013-12-31 | $1.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2013-10-01 to 2013-12-31 | $0.51 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2013-04-01 to 2013-12-31 | $1.62 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2013-10-01 to 2013-12-31 | 3,637,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2013-04-01 to 2013-12-31 | 3,591,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2013-04-01 to 2013-12-31 | $9.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Dividends paid | 9 months, 2013-04-01 to 2013-12-31 | $1.5m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2013-04-01 to 2013-12-31 | $15.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2013-12-31 | $2.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-12-31 | $20.6m | us-gaap:AssetsCurrent |
| Total assets | at 2013-12-31 | $92.6m | us-gaap:Assets |
| Current liabilities | at 2013-12-31 | $10.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-12-31 | $34.0m | us-gaap:Liabilities |
| Long-term debt | at 2013-12-31 | $16.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2013-12-31 | $58.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 24,441 characters.

### Forward Looking Statements

*This report contains information that may constitute “forward-looking statements.” Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, “Item 1A. Risk Factors” and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2013, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.*

### General Discussion

We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into three divisions across six physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries. Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments. We follow a philosophy of manufacturing a high quality product and providing a high level of on-going service for those products.

Our revenues come from two main sources — product sales, and parts and services. Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products, and acquisitions. Biological Indicator products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products and Continuous Monitoring systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Parts and service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we try to pass along cost increases in order to maintain our margins.

Gross profit is affected by our product mix, manufacturing efficiencies and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margins for some of the products have improved. There are, however, differences in gross margins between different product lines, and ultimately the mix of sales may continue to impact our overall gross margin.

Selling expense is driven primarily by labor costs, including salaries and commissions. Accordingly, it may vary with sales levels. Generally labor costs and amortization of intangible assets drive 60-70% of general and administrative expense. Research and development expense is predominantly comprised of labor costs and third party consultants.

In November 2013, we completed the Amega Acquisition whereby we acquired substantially all of the assets and certain liabilities of Amega for $12,268,000 and potential contingent consideration if the cumulative revenues for our Continuous Monitoring Division for the three years subsequent to the acquisition meet certain levels.

In November 2013, we completed the TempSys Acquisition whereby we acquired all of the common stock of TempSys for $9,826,000.

In July 2013, we completed the Suretorque Acquisition whereby we acquired essentially all of the assets of ST Acquisitions’ business involving the design, manufacturing, sale and service of its SureTorque line of bottle cap torque testing instrumentation for $1,821,000.

In May 2012, we completed the Bios Acquisition by acquiring specific assets and assuming certain liabilities of Bios, a New Jersey corporation, for $16,660,000 and potential contingent consideration based on revenue growth over a three year earn-out period.

In August 2013, we entered into an agreement whereby we sold our NuSonics product line for $661,000, which resulted in a pre-tax gain of $468,000.

### General Trends and Outlook

Our strategic objectives include growth both organically and through further acquisitions. During the year ended March 31, 2013, we continued to build our infrastructure to prepare for future growth, including the addition of key personnel to our operations, research and development, and finance teams. As needed, we continue to strengthen our infrastructure during the year ending March 31, 2014, including our information systems. We expect Sarbanes-Oxley (“SOX”) compliance costs to remain relatively flat during the year ending March 31, 2014, as we maintain our internal control structure while simultaneously making efficient and effective improvements.

The markets for our biological indicators remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for biological indicators is growing, as more countries focus on verifying the effectiveness of sterilization processes. Recent general economic conditions however have slowed the organic growth of our instruments business, due to the discretionary nature of these products. Additionally, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases. Demand for our instruments products and our newly acquired continuous monitoring systems, however, is still strong and we strive to maintain or grow revenues going forward.

We are working on several research and development projects that, if completed, may result in new products for both existing customers and in new markets. We are hopeful that both our Biological Indicators and Instruments Divisions will have new products available for sale in the coming year.

### Results of Operations

The following table sets forth, for the periods indicated, condensed consolidated statements of income data. The table and the discussion below should be read in conjunction with the accompanying condensed consolidated financial statements and the notes thereto appearing elsewhere in this report (in thousands, except percent data):

|  | Three Months Ended December 31, 2013 | 2012 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $13,116 | $11,361 | $1,755 | 15% |
| Cost of revenues | 5,410 | 4,414 | 996 | 23% |
| Gross profit | $7,706 | $6,947 | $759 | 11% |
| Gross margin | 59% | 61% | (2)% |  |
| Operating expenses |  |  |  |  |
| Selling | $1,595 | $1,223 | $372 | 30% |
| General and administrative | 2,781 | 2,759 | 22 | 1% |
| Research and development | 524 | 501 | 23 | 5% |
|  | $4,900 | $4,483 | $417 | 9% |
| Net income | $1,746 | $1,543 | $203 | 13% |
| Net profit margin | 13% | 14% | (1)% |  |

13

|  | Nine Months Ended December 31, 2013 | 2012 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $37,010 | $33,627 | $3,383 | 10% |
| Cost of revenues | 14,907 | 12,976 | 1,931 | 15% |
| Gross profit | $22,103 | $20,651 | $1,452 | 7% |
| Gross margin | 60% | 61% | (1)% |  |
| Operating expenses |  |  |  |  |
| Selling | $4,097 | $3,297 | $800 | 24% |
| General and administrative | 8,003 | 6,782 | 1,221 | 18% |
| Research and development | 1,639 | 1,399 | 240 | 17% |
|  | $13,739 | $11,478 | $2,261 | 20% |
| Net income | $5,538 | $5,891 | $(353) | (6)% |
| Net profit margin | 15% | 18% | (3)% |  |

### Revenues

The following table summarizes our revenues by source (in thousands, except percent data):

|  | Three Months Ended December 31, 2013 | 2012 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Biological Indicators | $5,317 | $5,154 | $163 | 3% |
| Instruments | 6,438 | 6,207 | 231 | 4% |
| Continuous Monitoring | 1,361 | — | 1,361 | 100% |
| Total | $13,116 | $11,361 | $1,755 | 15% |

|  | Nine Months Ended December 31, 2013 | 2012 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Biological Indicators | $16,181 | $15,590 | $591 | 4% |
| Instruments | 19,468 | 18,037 | 1,431 | 8% |
| Continuous Monitoring | 1,361 |  | 1,361 | 100% |
| Total | $37,010 | $33,627 | $3,383 | 10% |

#### Three and nine months ended December 31, 2013 versus December 31, 2012

Biological Indicators revenues for the three and nine months ended December 31, 2013 increased as compared to the prior year as a result of continued organic growth, achieved through existing customers and expansion into new markets.

Instruments revenues for the three and nine months ended December 31, 2013 increased as compared to the prior year primarily from organic growth in our gas flow calibration equipment and medical product lines and the acquisition of the SureTorque product line, partially offset by the disposal of our Nusonics product line in August 2013. Our other Instruments product lines remained relatively unchanged. The increase in Instruments revenues for the nine months ended December 31, 2013 as compared to the prior year was also impacted by the timing of the Bios Acquisition in the prior year.

### Gross Profit

The following summarizes our gross profit by segment (in thousands, except percent data):

|  | Three Months Ended December 31, 2013 | 2012 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Biological Indicators | $2,976 | $2,936 | $40 | 1% |
| Gross profit margin | 56% | 57% | (1)% |  |
| Instruments | 4,137 | 4,011 | 126 | 3% |
| Gross profit margin | 64% | 65% | (1)% |  |
| Continuous Monitoring | 593 | — | 593 | 100% |
| Gross profit margin | 44% | — | 100% |  |
| Total | $7,706 | $6,947 | $759 | 11% |
| Gross profit margin | 59% | 61% | (2)% |  |

|  | Nine Months Ended December 31, 2013 | 2012 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Biological Indicators | $9,019 | $8,890 | $129 | 1% |
| Gross profit margin | 56% | 57% | (1)% |  |
| Instruments | 12,491 | 11,761 | 730 | 6% |
| Gross profit margin | 64% | 65% | (1)% |  |
| Continuous Monitoring | 593 | — | 593 | 100% |
| Gross profit margin | 44% | — | 100% |  |
| Total | $22,103 | $20,651 | $1,452 | 7% |
| Gross profit margin | 60% | 61% | (1)% |  |

#### Three and nine months ended December 31, 2013 versus December 31, 2012

Biological Indicators gross profit margin percentage for the three and nine months ended December 31, 2013 remained relatively flat as compared to the prior year.

Instruments gross profit margin percentage for the three months ended December 31, 2013 decreased as compared to the prior year primarily due to increased manufacturing costs associated with migrating the operations associated with the Suretorque Acquisition to our Lakewood facility, partially offset by an increase in our gas flow calibration equipment product line due to increased revenues. Instruments gross profit margin percentage for the nine months ended December 31, 2103 decreased as compared to the prior year primarily as a result of the application of purchase accounting and increased manufacturing costs associated with migrating the operations associated with the Suretorque Acquisition to our Lakewood facility, partially offset by an increase in our gas flow calibration equipment product line due to increased revenues and the timing of the Bios Acquisition in the prior year.

Continuous Monitoring gross profit margin percentage for the three and nine months ended December 31, 2013 was negatively impacted by integration activities that commenced soon after the acquisitions were completed. These integration activities, which are ongoing, are expected to be substantially completed during the second half of our year ending March 31, 2015, at which time we expect that gross profit margin percentage for this segment to be closer to our historical results.

### Operating Expenses

Operating expenses for the three and nine months ended December 31, 2013 increased (decreased) as compared to the prior year as follows (in thousands):

|  | Increase (Decrease) Three Months Ended December 31, 2013 | Nine Months Ended December 31, 2013 |
| --- | ---: | ---: |
| **Selling** | $372 | $800 |
| **General and administrative** |  |  |
| Amortization | 147 | 20 |
| Chief Financial Officer transition | (526) | (526) |
| Personnel costs | 168 | 173 |
| Taxes and fees | (5) | 1,104 |
| Professional fees | 174 | 59 |
| Other, net | 64 | 391 |
|  | 22 | 1,221 |
| **Research and development** | 23 | 240 |
| **Operating expenses** | $417 | $2,261 |

#### Three and nine months ended December 31, 2013 versus December 31, 2012

*Selling —* Selling expenses for the three and nine months ended December 31, 2103 increased as compared to the prior year primarily due to the Amega, TempSys and Suretorque acquisitions, along with negligible increases from other product lines. Selling expenses for the nine months ended December 31, 2013 increased primarily due to the Amega, TempSys, Suretorque and Bios acquisitions.

*General and administrative —* General and administrative costs for the three and nine months ended December 31, 2013 increased as compared to the prior year due to increased amortization and personnel costs resulting from the Amega and TempSys acquisitions and increases in professional fees substantially offset by Chief Financial Officer transition costs incurred during the three and nine months ended December 31, 2012. The increase for the nine months ended December 31, 2013 as compared to the prior year was also impacted by the recording of a $1,106,000 accrual associated with not properly collecting and remitting sales tax in states in which we most likely had established nexus during prior periods.

*Research and development—* Research and development expenses for the three months ended December 31, 2013 was relatively flat as compared to the prior year. Research and development expenses for the nine months ended December 31, 2013 increased as compared to the prior year as a result of the Bios Acquisition and timing of external research and development consulting costs, as we continue our commitment to research and development.

### Net Income

Other income (expense) for the nine months ended December 31, 2013 increased as compared to the prior year as a result of the Nusonics Disposal. Our tax rate varies based upon many factors but in general, we anticipate that our effective tax rate will approximate 36.3%. Otherwise, net income varied with the changes in revenue, gross profit and operating expenses.

### Liquidity and Capital Resources

Our sources of liquidity include cash generated from operations, working capital, capacity under our Credit Facility and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources include quarterly dividends to stockholders, payment of debt obligations, long-term capital equipment expenditures and potential acquisitions.

Working capital is the amount by which current assets exceed current liabilities. We had working capital of $ 9,817,000 and $14,793,000 at December 31, 2013 and March 31, 2013, respectively. The decrease in working capital is primarily due to the use of cash for the repayment of long-term debt, the timing of the collection of accounts receivable, the recording of a $1,106,000 accrual associated with not properly collecting and remitting sales tax in states in which we most likely had established nexus during prior periods and impact of purchase accounting associated with the Amega and TempSys acquisitions.

In February 2012, we entered into the Credit Facility, which is comprised of a three year agreement for a $20,000,000 revolving line of credit and up to $1,000,000 of letters of credit. Funds from the Credit Facility may be used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures. In November 2013, we borrowed $18,000,000 against the Line of Credit to partially finance the TempSys and Amega Acquisitions. There was $16,000,000 outstanding under the Line of Credit at December 31, 2013 and we had unused capacity of $4,000,000. In January 2014, we made an additional principal payment of $1,000,000.

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We believe that we have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions.

On November 7, 2005, our Board of Directors authorized a program to repurchase up to 300,000 shares of our outstanding common stock. Under the plan, the shares may be purchased from time to time in the open market at prevailing prices or in negotiated transactions off the market. Shares purchased will be canceled and repurchases will be made with existing cash reserves. We do not maintain a set policy or schedule for our buyback program. We have purchased 161,631 shares of common stock under this program from inception through December 31, 2013.

We have been paying regular quarterly dividends since 2003. Dividends per share paid by quarter were as follows:

|  | Year ending March 31, 2014 | 2013 |
| --- | ---: | ---: |
| First quarter | $0.14 | $0.13 |
| Second quarter | 0.14 | 0.13 |
| Third quarter | 0.15 | 0.14 |
| Fourth quarter | — | 0.14 |

In January 2014, our Board of Directors declared a quarterly cash dividend of $0.15 per share of common stock, payable on March 17, 2014, to stockholders of record at the close of business on February 28, 2014.

### Cash Flows

Our cash flows from operating, investing and financing activities were as follows (in thousands):

|  | Nine Months Ended December 31, 2013 | 2012 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $9,474 | $8,451 |
| Net cash used in investing activities | (22,905) | (17,316) |
| Net cash provided by financing activities | 11,585 | 4,396 |

Net cash provided by operating activities for the nine months ended December 31, 2013 increased primarily due to positive results from efforts to collect long-outstanding receivables partially offset by higher expenses associated with the timing of the TempSys and Amega Acquisitions and the timing of other working capital expenditures.

Net cash used in investing activities for the nine months ended December 31, 2013 resulted from the $11,268,000 Amega Acquisition, the $9,769,000 TempSys Acquisition (net of cash acquired), the $1,721,000 Suretorque Acquisition and the purchase of $808,000 of property, plant and equipment partially offset by the proceeds from the NuSonics Disposal. Net cash used in investing activities for the nine months ended December 31, 2012 resulted from the $16,660,000 Bios Acquisition and the purchase of $656,000 of property, plant and equipment

Net cash used in financing activities for the nine months ended December 31, 2013 resulted from borrowings under our Line of Cedit of $18,000,000 and proceeds from the exercise of stock options of $1,067,000, partially offset by the repayment of debt of $6,000,000 and the payment of dividends of $1,467,000. Net cash provided by financing activities for the nine months ended December 31, 2012 resulted from borrowings under our Line of Credit of $11,000,000 and proceeds from the exercise of stock options of $794,000, partially offset by the repayment of debt of $6,000,000 and the payment of dividends of $1,341,000.

At December 31, 2013, we had contractual obligations for open purchase orders of approximately $1,500,000 for routine purchases of supplies and inventory, which would be payable in less than one year.

In November 2013, we completed the Amega Acquisition for a purchase price of $12,268,000, consisting of a cash payment of $11,268,000 at closing and a $1,000,000 holdback amount that is expected to be settled in November 2014. In addition, under the terms of the Amega Agreement, we are required to pay contingent consideration if the cumulative revenues for our Continuous Monitoring Division for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $10,000,000 and is based upon a sliding scale of three-year cumulative revenues between $31,625,000 and $43,500,000.

In July 2013, we completed the SureTorque Acquisition for a purchase price of $1,821,000, consisting of a cash payment of $1,721,000 at closing and a $100,000 holdback amount that is expected to be settled on July 1, 2014.

As part of our Bios Acquisition, the Bios Agreement includes a provision for contingent consideration based on revenue growth over a three year earn-out period. The contingent consideration arrangement requires us to pay Bios if cumulative revenues from the acquisition for the three years subsequent to the acquisition exceed $22,127,000. The potential undiscounted future payment that we could be required to make ranges from $0 to $6,710,000.

### Critical Accounting Estimates

Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed consolidated financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2013 in the Critical Accounting Policies and Estimates section of “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

## Controls and procedures

As filed, 2,721 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of December 31, 2013. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective at December 31, 2013.

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Management evaluated the effectiveness of our internal control over financial reporting based on the framework in “Internal Control — Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of December 31, 2013. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at December 31, 2013.

### Changes in Internal Control Over Financial Reporting

There were no significant changes in our internal control over financial reporting that occurred during the nine months ended December 31, 2013, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 1,901 characters.

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2013, under the heading “Part I — Item 1A. Risk Factors.” There have been no material changes to those risk factors other than the following:

### Catastrophic events or environmental conditions may disrupt our business.

A disruption or failure of our systems or operations because of a major weather event, cyber-attack, terrorist attack, or other catastrophic event could cause delays in completing sales, providing services or performing other mission-critical functions. A catastrophic event that results in the destruction or disruption of any of our critical business or IT systems could harm our ability to conduct normal business operations. Abrupt political change, terrorist activity, and armed conflict pose a risk of general economic disruption in affected countries, which may increase our operating costs or adversely affect our revenues. These conditions also may add uncertainty to the timing and budget for purchase/investment decisions by our customers, and may result in supply chain disruptions for hardware manufacturers, either of which may adversely affect our revenue. The long-term effects of climate change on the global economy in general or the Industrial Instruments industry in particular are unclear. Environmental regulations or changes in the supply, demand or available sources of energy may affect the availability or cost of goods and services, including natural resources, necessary to run our business. Changes in weather where we operate may increase the costs of powering and maintaining the equipment we need to produce our product lines.

Filed Feb 5, 2014.
Source: SEC EDGAR, the filing index for accession 0001104659-14-006596. Last ingested by Listed: Nov 13, 2026, 07:45 ET. No prices; not investment advice.
